|
US5976573A
(en)
|
1996-07-03 |
1999-11-02 |
Rorer Pharmaceutical Products Inc. |
Aqueous-based pharmaceutical composition
|
|
FR2756739B1
(en)
*
|
1996-12-05 |
2000-04-28 |
Astra Ab |
NEW BUDESONIDE FORMULATION
|
|
WO1999032125A1
(en)
*
|
1997-12-23 |
1999-07-01 |
Schering Corporation |
Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
|
|
US6248308B1
(en)
|
1998-04-14 |
2001-06-19 |
Sepracor Inc. |
Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma
|
|
US6245785B1
(en)
|
1998-11-30 |
2001-06-12 |
Warner Lambert Company |
Dissolution of triprolidine hydrochloride
|
|
EP1020233A1
(en)
|
1999-01-13 |
2000-07-19 |
The Procter & Gamble Company |
Dosing and delivering system
|
|
DE19924525A1
(en)
*
|
1999-05-28 |
2000-11-30 |
Ruediger Scheunemann |
Composition containing topical glucocorticoid and detumescent, useful for treating e.g. hayfever and sinusitis
|
|
IT1313567B1
(en)
*
|
1999-07-27 |
2002-09-09 |
Zambon Spa |
USE OF N-ACETYL-CISTEIN FOR THE PREPARATION OF TOPICAL PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ALLERGIC PATHOLOGIES OF
|
|
GB9918559D0
(en)
*
|
1999-08-07 |
1999-10-06 |
Glaxo Wellcome Kk |
Novel pharmaceutical formulation
|
|
DE19947234A1
(en)
*
|
1999-09-30 |
2001-04-05 |
Asta Medica Ag |
New combination of loteprednol and antihistamines
|
|
CA2383970A1
(en)
*
|
1999-10-08 |
2001-04-19 |
Schering Corporation |
Topical nasal treatment using desloratadine
|
|
CA2405169C
(en)
|
2000-04-03 |
2011-07-26 |
Battelle Memorial Institute |
Devices and formulations
|
|
US6777400B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
|
US6759398B2
(en)
|
2000-08-05 |
2004-07-06 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative
|
|
GB0019172D0
(en)
|
2000-08-05 |
2000-09-27 |
Glaxo Group Ltd |
Novel compounds
|
|
US6777399B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
|
US6787532B2
(en)
|
2000-08-05 |
2004-09-07 |
Smithkline Beecham Corporation |
Formulation containing anti-inflammatory androstane derivatives
|
|
US6858596B2
(en)
|
2000-08-05 |
2005-02-22 |
Smithkline Beecham Corporation |
Formulation containing anti-inflammatory androstane derivative
|
|
US6750210B2
(en)
|
2000-08-05 |
2004-06-15 |
Smithkline Beecham Corporation |
Formulation containing novel anti-inflammatory androstane derivative
|
|
US6858593B2
(en)
|
2000-08-05 |
2005-02-22 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
|
ATE416184T1
(en)
|
2000-08-05 |
2008-12-15 |
Glaxo Group Ltd |
17.BETA.-CARBOTHIOATE 17.ALPHA.- ARYLCARBONYLOXYLOXY ANDROSTANDE DERIVATIVES AS ANTIPHLOGISTIC MEDICATIONS
|
|
GB0021927D0
(en)
*
|
2000-09-07 |
2000-10-25 |
Glaxo Group Ltd |
Use of pharmaceutical combination
|
|
AU2002214030A1
(en)
*
|
2000-10-31 |
2002-05-15 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Novel medicament compositions consisting of tiotropium salts and antihistamines for treating respiratory illnesses
|
|
BR0115016A
(en)
*
|
2000-10-31 |
2005-05-03 |
Boehringer Ingelheim Pharma |
Formulation of inhalable solution with a tiotropium salt
|
|
US20020137764A1
(en)
|
2000-10-31 |
2002-09-26 |
Karin Drechsel |
Inhalable formulation of a solution containing a tiotropium salt
|
|
US7776315B2
(en)
|
2000-10-31 |
2010-08-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on anticholinergics and additional active ingredients
|
|
UA77656C2
(en)
|
2001-04-07 |
2007-01-15 |
Glaxo Group Ltd |
S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
|
|
WO2002088167A1
(en)
|
2001-04-30 |
2002-11-07 |
Glaxo Group Limited |
Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
|
|
GB2389530B
(en)
|
2002-06-14 |
2007-01-10 |
Cipla Ltd |
Pharmaceutical compositions
|
|
JP4320217B2
(en)
*
|
2002-07-10 |
2009-08-26 |
剤盛堂薬品株式会社 |
Oral preparation for rhinitis
|
|
JP4746318B2
(en)
|
2002-08-30 |
2011-08-10 |
ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング |
A pharmaceutical composition for the treatment of allergic rhinitis comprising a combination of ciclesonide and an antihistamine
|
|
KR101018527B1
(en)
|
2002-09-20 |
2011-03-03 |
에프엠씨 코포레이션 |
Cosmetic composition containing microcrystalline cellulose
|
|
CA2504200A1
(en)
*
|
2002-11-12 |
2004-05-27 |
Alcon, Inc. |
The use of an anti-allergy agent and a steroid to treat allergic rhinitis
|
|
US20050192261A1
(en)
*
|
2003-09-15 |
2005-09-01 |
Jost-Price Edward R. |
Methods and reagents for the treatment of immunoinflammatory disorders
|
|
WO2005030331A1
(en)
*
|
2003-09-26 |
2005-04-07 |
Fairfield Clinical Trials, Llc |
Combination antihistamine medication
|
|
US20070020299A1
(en)
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
|
|
PL1744760T3
(en)
*
|
2004-04-22 |
2015-04-30 |
Acucort Ab |
Pharmaceutical compositions for acute glucocorticoid therapy
|
|
US20050255154A1
(en)
|
2004-05-11 |
2005-11-17 |
Lena Pereswetoff-Morath |
Method and composition for treating rhinitis
|
|
BRPI0517891A
(en)
|
2004-11-24 |
2008-10-21 |
Medpointe Healthcare Inc |
compositions comprising azelastine and methods of use thereof
|
|
US20070020330A1
(en)
|
2004-11-24 |
2007-01-25 |
Medpointe Healthcare Inc. |
Compositions comprising azelastine and methods of use thereof
|
|
EP1919450B1
(en)
*
|
2005-09-01 |
2014-06-11 |
Meda AB |
Antihistamine- and corticosteroid-containing liposome composition and its use for the manufacture of a medicament for treating rhinitis and related disorders
|
|
US12370352B2
(en)
|
2007-06-28 |
2025-07-29 |
Cydex Pharmaceuticals, Inc. |
Nasal and ophthalmic delivery of aqueous corticosteroid solutions
|
|
JP2010531898A
(en)
*
|
2007-06-28 |
2010-09-30 |
サイデックス・ファーマシューティカルズ・インコーポレイテッド |
Delivery of aqueous corticosteroids to the nose and eyes
|
|
PT3943069T
(en)
|
2009-03-17 |
2025-02-21 |
Nicox Ophthalmics Inc |
Ophthalmic formulations of cetirizine and methods of use
|
|
US8569273B2
(en)
|
2009-03-17 |
2013-10-29 |
Aciex Therapeutics, Inc. |
Ophthalmic formulations of cetirizine and methods of use
|
|
CN103269687B
(en)
*
|
2011-01-04 |
2016-09-14 |
伊斯塔制药公司 |
4-[(S)-(4-chlorophenyl)-2-pyridinylmethoxy compositions
|
|
FR2970180B1
(en)
*
|
2011-01-06 |
2013-08-02 |
Substipharm Dev |
PROCESS FOR THE PREPARATION OF AQUEOUS PHARMACEUTICAL SUSPENSIONS COMPRISING AN EFFICIENT DRUG IN THE TREATMENT OF RHINITIS
|
|
WO2013017821A1
(en)
|
2011-08-02 |
2013-02-07 |
Cipla Limited |
Pharmaceutical composition comprising ebastine and fluticasone
|
|
CN106074387B
(en)
*
|
2016-08-15 |
2019-09-13 |
辽宁大学 |
Thixotropic triamcinolone acetonide nasal spray and preparation method thereof
|
|
US20200261433A1
(en)
*
|
2019-02-15 |
2020-08-20 |
Ferrer Medical Innovations, LLC |
Nasal spray compositions and related treatment methods
|
|
EP3941450A4
(en)
|
2019-03-22 |
2022-12-21 |
Dbbh, Llc |
Intranasally administered antihistamines and uses thereof
|
|
CA3179806A1
(en)
*
|
2020-04-14 |
2021-10-21 |
Glaxosmithkline Consumer Healthcare Holdings (Us) Llc |
Nasal spray formulation with moisturizing benefits
|
|
US10874650B1
(en)
*
|
2020-04-24 |
2020-12-29 |
Ferrer Medical Innovations, LLC |
Antiviral and virucidal nasal spray compositions and related treatment methods
|
|
WO2023233570A1
(en)
*
|
2022-06-01 |
2023-12-07 |
佐藤製薬株式会社 |
Nasal drip composition
|